logo
Plus   Neg
Share
Email

Stock Alert: Intercept Pharmaceuticals Down 14%

Shares of Intercept Pharmaceuticals Inc. (ICPT) tanked nearly 14% on Friday morning after the pharma company said that FDA has postponed its advisor committee meeting for new liver disease drug.

ICPT is currently trading at $78.95, down $12.74 or 13.89%, on the Nasdaq.

Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases.

The company said the U.S. Food and Drug Administration has notified that advisory committee meeting scheduled for June 9, 2020 related to the new drug application for obeticholic acid for the treatment of liver fibrosis has been postponed.

The postponement will accommodate the review of additional data requested by the FDA that the company intends to submit within the next week.

The FDA has indicated that it will reach out to Intercept in the near future with a new proposed AdCom date.

Intercept now anticipates that the FDA's review of its NDA will extend beyond the Prescription Drug User Fee Act (PDUFA) target action date of June 26, 2020.

"While this delay was unanticipated, following our most recent dialogue with the FDA we believe that the additional data being submitted will be important in facilitating a more informed discussion at the AdCom," said Mark Pruzanski, M.D., President and Chief Executive Officer of Intercept.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Latam Airlines Group SA, one of the largest air carrier in South America, has filed for bankruptcy protection in New York amid the ongoing Covid-19 pandemic, which has grounded flights worldwide. This Chapter 11 filing allows Latam to work with its creditors and other stakeholders to reduce its debt,... Pizza Hut said it is giving away 500,000 free pizzas to 2020 graduates in the Unites States. The pizza chain, owned by Yum! Brands, offers one free medium 1-topping pizza to all diploma/degree earning individuals until supplies last. The company is partnering with America's dairy farmers for the offer, which can be claimed until Thursday and redeemed until June 4. Merck & Co. Inc. on Tuesday announced deals, including an acquisition and two collaborations that will enable the U.S. drugmaker to join the race to develop coronavirus vaccines and drugs. Shares of Merck were rising almost 4 percent in the pre-market. Merck said it has agreed to acquire privately-held Themis, an Austria-based company focused on vaccines and immune-modulation therapies.
Follow RTT